Brief: Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study
21/07/2025 11:05
July 21 (Reuters) - Alkermes Plc ALKS.O: ALKERMES ANNOUNCES POSITIVE TOPLINE RESULTS FROM VIBRANCE-1 PHASE 2 STUDY OF ONCE-DAILY ALIXOREXTON IN PATIENTS WITH NARCOLEPSY TYPE 1 Source text: ID:nPn9wZvgJa Further company coverage: ALKS.O ((Reuters.Briefs@thomsonreuters.com;))